Persistence of immune response following bivalent HPV vaccination: A follow-up study among girls routinely vaccinated with a two-dose schedule

In this cohort study, we examined antibody levels and avidity after a two-dose schedule (0, 6 months) of the bivalent HPV-vaccine in girls routinely vaccinated in the Dutch HPV-vaccination program, up to 2 years following vaccination. A blood sample at 7, 12 and 24 months after the first dose and qu...

Full description

Saved in:
Bibliographic Details
Published in:Vaccine 2018-11, Vol.36 (49), p.7580-7587
Main Authors: Schurink-van 't Klooster, Tessa M., Donken, Robine, Schepp, Rutger M., van der Klis, Fiona R.M., de Melker, Hester E.
Format: Article
Language:English
Subjects:
Adolescent
Age
Antibodies
Antibodies, Neutralizing - blood
Antibodies, Viral - blood
Antibody Affinity
Antibody concentration
Antibody Formation
Avidity
Child
Clinical trials
Cohort Studies
Country of birth
Demographics
Disease control
Female
Follow-Up Studies
Girls
GMC
HPV
Human papillomavirus
Human papillomavirus 16
Human papillomavirus 18
Humans
Immune response
Immune system
Immunization Programs
Immunization Schedule
Immunoassay
Immunoglobulins
Immunology
Infectious diseases
Kinetics
Licenses
Papillomavirus Infections - prevention & control
Papillomavirus Vaccines - administration & dosage
Papillomavirus Vaccines - immunology
Participation
Phlebotomy
Public health
Questionnaires
Sampling methods
Statistical analysis
Surveys and Questionnaires
Teenagers
Two-dose schedule
Vaccination
Vaccine
Vaccines
Virus-like particles
Viruses
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:In this cohort study, we examined antibody levels and avidity after a two-dose schedule (0, 6 months) of the bivalent HPV-vaccine in girls routinely vaccinated in the Dutch HPV-vaccination program, up to 2 years following vaccination. A blood sample at 7, 12 and 24 months after the first dose and questionnaire data were collected (n = 56). HPV type-specific antibody concentrations (lU/ml) against seven types (HPV16/18/31/33/45/52/58) were assessed using a validated virus-like particles (VLP) multiplex immunoassay. Avidity was tested using a modification of this assay. Seropositivity for vaccine types HPV 16 and 18 was 100% up to month 24, but declined for HPV-types 31/33/45/52/58, although not statistically significant for HPV45. All Geometric Mean Concentrations (GMCs) declined by months 12 and 24, but remained high for HPV16/18. Between month 7 and 12, GMCs declined more for other types. High avidity antibodies were induced up to 24 months for vaccine types (75%, 76–78% and 81–82% at months 7, 12 and 24, respectively), but for other types antibody avidity was 16–29% at month 7, 20–32% at month 12 and 19–32% at month 24. GMCs declined over time for HPV-types 16/18/31/33/45/52/58, but remained high for vaccine-types HPV16/18 up to 24 months of follow-up. Antibody avidity was >75% for vaccine types but
ISSN:0264-410X
1873-2518
DOI:10.1016/j.vaccine.2018.10.018